.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Cerilliant
US Army
Merck
QuintilesIMS
Farmers Insurance
Moodys
Johnson and Johnson
Novartis
Federal Trade Commission

Generated: December 14, 2017

DrugPatentWatch Database Preview

ADRENACLICK Drug Profile

« Back to Dashboard

Which patents cover Adrenaclick, and when can generic versions of Adrenaclick launch?

Adrenaclick is a drug marketed by Impax Labs Inc and is included in one NDA. There is one patent protecting this drug.

This drug has forty-three patent family members in fifteen countries.

The generic ingredient in ADRENACLICK is epinephrine. There are nineteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Impax Labs IncADRENACLICKepinephrineINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-003Nov 25, 2009BXRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Impax Labs IncADRENACLICKepinephrineINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-004Nov 25, 2009BXRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ADRENACLICK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Impax Labs IncADRENACLICKepinephrineINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-003Nov 25, 2009► Subscribe► Subscribe
Impax Labs IncADRENACLICKepinephrineINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS020800-004Nov 25, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ADRENACLICK

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,297,136Medicine injection devices and methods► Subscribe
7,931,618Apparatuses and methods for injecting medicines to a desired depth► Subscribe
8,187,224Methods performed by medicine injection apparatuses► Subscribe
7,927,303Medicine injection devices and methods► Subscribe
7,621,891Method and apparatus for delivering epinephrine► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ADRENACLICK

Country Document Number Estimated Expiration
China101072604► Subscribe
San MarinoAP200700024► Subscribe
South Africa200704516► Subscribe
China101850143► Subscribe
San MarinoAP200700023► Subscribe
Hong Kong1110811► Subscribe
San MarinoP200700023► Subscribe
World Intellectual Property Organization (WIPO)2006063015► Subscribe
BrazilPI0518415► Subscribe
Russian Federation2007125259► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Citi
Chubb
Cipla
Covington
Deloitte
Julphar
Fuji
Argus Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot